The global Electronic Health Records (EHR) market is experiencing a significant capital expansion, driven by widespread public sector digitisation mandates and the rapid clinical adoption of cloud-native architectures. Financial projections indicate the global EHR market will generate $31.7 Billion in 2026, rising to $33.4 Billion in 2027, $35.3 Billion in 2028, and ultimately reaching $39.2 Billion by 2030. Inpatient EHR systems command a dominant 55% share of this global ma

The transition of the consumer biometrics and wearable informatics landscape has reached a critical inflection point. On May 19th, 2026, Google initiated a mandatory software deployment that formally rebranded and structurally consolidated the legacy Fitbit application into Google Health 5.0. This update, which achieved full global availability on May 26th, 2026, represents a fundamental re-engineering of Google’s health and fitness architecture. Rather than treating the acqu

This has been a big week for European HealthTech, largely anchored by the major HIMSS26 Europe conference in Copenhagen alongside sweeping regulatory actions from the European Commission. The European MedTech sector is experiencing its most critical regulatory and commercial shake-up in years. A wave of structural overhauls from Brussels and London is colliding with a mandatory compliance deadline next week, completely shifting the operating landscape for device manufacturers

The consumer health technology sector is on the cusp of one of its most consequential public market moments since the 2021 SPAC boom, but this time with real revenue, real retention, and real business models. The combined pre-IPO valuation of all three exceeds $23 Billion, Oura at ~$11 Billion, WHOOP at $10.1 Billion and Strava at ~$2.2 Billion, making this the largest cluster of consumer health listings since the sector was born.

The consolidation of GHO Capital and CBC Group represents a notable evolution in the alternative asset management landscape, characterised by the rise of "mega-specialist" managers. This transaction also highlights the strategic role of technology and artificial intelligence (AI) as critical tools for value creation and operational efficiency in the life sciences sector. As noted by the executive leadership, the integration of AI applications into drug discovery, diagnostic i

The governance reforms enacted in late 2025 have established a highly disciplined, efficient capital allocation framework at Medtronic. Under the oversight of the Growth and Operating Committees, corporate leadership has successfully transitioned from a period of operational consolidation to an offensive M&A posture. The acquisitions of CathWorks, Scientia Vascular, and SPR Therapeutics demonstrate this strategic alignment, targeting high-growth, minimally invasive, and softw

Healthcare technology stands out as one of the strongest themes in the 2026 CNBC Disruptor 50, but it is now framed almost entirely through an AI and data infrastructure lens rather than classic digital health point solutions.

Alcidion Group (ASX: ALC) signed an Asset Sale Agreement on 16th May 2026 to acquire three Kyra patient flow products from Telstra Health: Kyra Patient Flow Manager, Kyra Queue Manager, and Kyra IQ. The upfront cash consideration is $3.0 Million, funded from Alcidion's existing cash reserves of $15.1 Million (no debt as of 31st March 2026), with a further earn-out of up to $1.0 Million tied to recurring revenue thresholds over 12 months post-completion. Completion is expected

On May 19th, 2026, ResMed (NYSE: RMD, ASX: RMD), a prominent global health technology company specialising in sleep, breathing and home-delivered respiratory care and ŌURA, the manufacturer of the leading smart ring, announced a strategic partnership. This cross-industry collaboration represents a structured initiative to connect daily consumer wellness tracking with professional medical diagnostic and treatment networks. By linking Oura's passive biometric telemetry with Res

They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​

The healthcare sector is undergoing a profound structural evolution as artificial intelligence (AI) transitions from an assistive, reactive tool into an autonomous execution layer. According to financial assessments, global AI expenditure is projected to rise from $1.76 Trillion in 2025 to $2.52 Trillion in 2026, before reaching $3.34 Trillion in 2027. A significant concentration of venture capital is driving this transformation; AI firms raised approximately $242 Billion in

The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a ri

The European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity. For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user

The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of speculative experimentation into what industry analysts categorise as the era of industrial maturity. This evolution is characterised by a "flight to quality," where the market has bifurcated into a high-conviction environment for category leaders and a severe capital squeeze for mid-stage ventures that fail to demonstrate immedi

The healthcare industry in 2026 has transitioned from a period of experimental artificial intelligence fervour to a phase of rigorous industrialisation, where the value of technology is measured by its ability to stabilise margins and secure sensitive data rather than its capacity for high-profile public spectacle. International Business Machines (IBM), having navigated a decade of volatility in its Watson Health division, has executed a profound strategic re-entry into the s